急性胆嚢炎の世界市場 (～2027年)：タイプ・原因・診断 (超音波検査・胆管シンチグラフィー・CTスキャン・ERCP・その他)・治療・エンドユーザー・地域別の競合予測・機会

世界の急性胆嚢炎の市場は2023年から2027年にかけて高いCAGRで成長すると予測されています。

同市場の成長は、胆嚢結石の発生数の増加に起因しています。また、製薬企業によるパイプライン薬のR&Dの進歩や、老年人口の増加、健康状態の悪化傾向なども今後の市場成長をさらに後押しする見通しです。

当レポートでは、世界の急性胆嚢炎の市場を調査し、市場概要、市場規模の推移・予測、各種区分・地域/主要国別の内訳、市場への各種影響因子の分析、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 製品概要

第2章 調査手法

第3章 COVID-19：世界の急性胆嚢炎市場に与える影響

第4章 エグゼクティブサマリー

第5章 VOC (顧客の声)

第6章 世界の急性胆嚢炎市場の見通し

• 市場規模・予測
• 市場シェア・予測
  • タイプ別（結石性急性胆嚢炎・無石性急性胆嚢炎）
  • 原因別（胆嚢結石・腫瘍・胆管閉塞・微生物感染・その他）
  • 診断別（超音波検査・胆管シンチグラフィー・CTスキャン・ERCP・その他）
  • 治療別（外科的・非外科的）
  • エンドユーザー別（病院および診療所・外来手術センター・その他）
  • 企業別
  • 地域別
• 製品市場マップ

第7章 北米の急性胆嚢炎市場の見通し

• 市場規模・予測
• 市場シェア・予測
  • タイプ別
  • 原因別
  • 診断別
  • 治療別
  • エンドユーザー別
  • 国別
• 国別分析

第8章 欧州の急性胆嚢炎市場の見通し

• 市場規模・予測
• 市場シェア・予測
  • タイプ別
  • 原因別
  • 診断別
  • 治療別
  • エンドユーザー別
  • 国別
• 国別分析

第9章 アジア太平洋の急性胆嚢炎市場の見通し

• 市場規模・予測
• 市場シェア・予測
  • タイプ別
  • 原因別
  • 診断別
  • 治療別
  • エンドユーザー別
  • 国別
• 国別分析

第10章 南米の急性胆嚢炎市場の見通し

• 市場規模・予測
• 市場シェア・予測
  • タイプ別
  • 原因別
  • 診断別
  • 治療別
  • エンドユーザー別
  • 国別
• 国別分析

第11章 中東およびアフリカの急性胆嚢炎市場の見通し

• 市場規模・予測
• 市場シェア・予測
  • タイプ別
  • 原因別
  • 診断別
  • 治療別
  • エンドユーザー別
  • 国別
• 国別分析

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向・市場展開

第14章 競合情勢

• 競合の見通し
• 企業プロファイル（主要5社のSWOT分析）
  • Boston Scientific Corporation
  • Fresenius Kabi AG
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Limited
  • Merck & Co., Inc.
  • Becton, Dickinson and Company
  • Simulab Corporation
  • AbbVie, Inc.
  • Fortimedix Surgical BV

第15章 戦略的提言

Global acute cholecystitis market is projected to accomplish an extraordinary growth in the forecast period, 2023-2027 with an impressive CAGR. The market growth can be attributed to the rising instances of gall bladder stone issues. The population is now more concerned and aware of the condition and demanding efficient and effective treatment for the same thereby aiding to the growth of the global acute cholecystitis market in the upcoming five years. Moreover, rapidly increasing research and advancement in the pharmaceutical department that has effective drugs in the pipeline of market launch is further enunciating the growth factors of the global acute cholecystitis market in the next five years. Increasing geriatric population and their tendency of weaker health and poor health conditions are further aiding the growth of the market in the near future.

Health insurances, governmental schemes have made it more feasible for the patients to afford the treatments ad thus supporting the growth of the market. The market may experience a mild restraint due to health conscious consumers that have now changed food habits and are rejuvenating their bodies with healthier food.

Market Segmentation

The global acute cholecystitis market is segmented by type, cause, diagnostic procedure, treatment, end user, regional distribution, and competitional landscape. Based on type, the market is differentiated between calculous acute cholecystitis and acalculous acute cholecystitis. By cause, the market is further segmented into gall bladder stones, tumor, bile duct blockage, microbial infection, and others. Based on diagnostic procedure, the market is fragmented into ultrasonography, cholescintigraphy, CT scan, ERCP (endoscopic retrograde cholangiopancreatography), and others. By treatment the market is differentiated between surgical and non-surgical. Based on end user, the market is bifurcated into hospitals & clinics, ambulatory surgical centers, and others. The market analysis also studies the regional segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Based on type, Acute Cholecystitis May Lead Market Growth

Based on type, the market is further divided between calculous acute cholecystitis and acalculous acute cholecystitis. Depending on the obstruction site the acute cholecystitis is of two types. Acute cholecystitis is a medical condition where stone-like obstructions are accumulated in the gallbladder, or the gastro-intestinal tube that connects gallbladder to the small intestine. If the obstruction is at the gall bladder duct it is termed as calculous acute cholecystitis and if the obstruction is at any other site in the gall bladder or the tube, it is termed as acalculous acute cholecystitis. Calculous acute cholecystitis is a worse condition of gall bladder condition and requires immediate attention thereby is anticipated to hold the larger market revenue shares and assert its dominance over the market segment. Acalculous acute cholecystitis is also an emergency situation but is comparatively less painful and may register significant growth in the market shares in the next five years.

Company Profile

Holding the major shares of the global acute cholecystitis market are Boston Scientific Corporation, Fresenius Kabi AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Merck & Co., Inc., Becton, Dickinson and Company, Simulab Corporation, AbbVie, Inc., Fortimedix Surgical BV, among others. Market players are actively involved in the research and technological development in the medical device and testing kit developments diagnosing the condition at an earlier stage. The advanced technology has made it possible for the healthcare industry to provide excellent healthcare services for acute cholecystitis. Further advancement would aid the market value and brand establishment in the future five years.

Years considered for this report:

Historical Years: 2017-2020

Base Year: 2021

Estimated Year: 2022

Forecast Period: 2023-2027

Objective of the Study:

• To analyze the historical growth of the market size of global acute cholecystitis market from 2017 to 2020.
• To estimate and forecast the market size of global acute cholecystitis market from 2021 to 2027 and growth rate until 2027.
• To classify and forecast global acute cholecystitis market based on type, cause, diagnostic procedure, treatment, end user, regional distribution, and competitional landscape.
• To identify dominant region or segment in the global acute cholecystitis market.
• To identify drivers and challenges for global acute cholecystitis market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global acute cholecystitis market.
• To identify and analyze the profile of leading players operating in global acute cholecystitis market.
• To identify key sustainable strategies adopted by market players in global acute cholecystitis market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and distributors across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals, surgical centers, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of global acute cholecystitis market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

• Hospitals, medical practitioners, end users, and other stakeholders
• Distributers and suppliers of products and other stakeholders
• Organizations, forums, and alliances related to acute cholecystitis
• Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as hospitals, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global Acute Cholecystitis market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Global Acute Cholecystitis Market, By Type:

Calculous Acute Cholecystitis

Acalculous Acute Cholecystitis

• Global Acute Cholecystitis Market, By Cause:

Gall Bladder Stones

Tumor

Bile Duct Blockage

Microbial Infection

Others

• Global Acute Cholecystitis Market, By Diagnostic Procedure:

Ultrasonography

Cholescintigraphy

CT Scan

ERCP (Endoscopic Retrograde Cholangiopancreatography)

Others

• Global Acute Cholecystitis Market, By Treatment:

Surgical

Non-Surgical

• Global Acute Cholecystitis Market, By End User:

Hospitals & Clinics

Ambulatory Surgical Centers

Others

• Global Acute Cholecystitis Market, By Region:

North America

• United States
• Canada
• Mexico

Europe

• Germany
• France
• United Kingdom
• Italy
• Spain
• Sweden

Asia-Pacific

• China
• Japan
• India
• South Korea
• Australia
• Thailand
• Bangladesh

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Turkey

South America

• Brazil
• Argentina
• Colombia
• Chile

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global acute cholecystitis market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Acute Cholecystitis Treatment Market

4. Executive Summary

5. Voice of Customer

• 5.1. Factors Contributing to Prevalence of Acute Cholecystitis
• 5.2. Prevalence of Acute Cholecystitis, By Gender
• 5.3. Prevalence of Acute Cholecystitis, By Age Group
• 5.4. Preferred choice of Treatment for Acute Cholecystitis

6. Global Acute Cholecystitis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Calculous Acute Cholecystitis v/s Acalculous Acute Cholecystitis)
  • 6.2.2. By Cause (Gall Bladder Stones, Tumor, Bile Duct Blockage, Microbial Infection, Others)
  • 6.2.3. By Diagnostic Procedure (Ultrasonography, Cholescintigraphy, CT Scan, ERCP (Endoscopic Retrograde Cholangiopancreatography), Others)
  • 6.2.4. By Treatment (Surgical v/s Non-Surgical)
  • 6.2.5. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
  • 6.2.6. By Company (2021)
  • 6.2.7. By Region
• 6.3. Product Market Map

7. North America Acute Cholecystitis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Cause
  • 7.2.3. By Diagnostic Procedure
  • 7.2.4. By Treatment
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Acute Cholecystitis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Cause
      • 7.3.1.2.3. By Diagnostic Procedure
      • 7.3.1.2.4. By Treatment
      • 7.3.1.2.5. By End User
  • 7.3.2. Mexico Acute Cholecystitis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Cause
      • 7.3.2.2.3. By Diagnostic Procedure
      • 7.3.2.2.4. By Treatment
      • 7.3.2.2.5. By End User
  • 7.3.3. Canada Acute Cholecystitis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Cause
      • 7.3.3.2.3. By Diagnostic Procedure
      • 7.3.3.2.4. By Treatment
      • 7.3.3.2.5. By End User

8. Europe Acute Cholecystitis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Cause
  • 8.2.3. By Diagnostic Procedure
  • 8.2.4. By Treatment
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Acute Cholecystitis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Cause
      • 8.3.1.2.3. By Diagnostic Procedure
      • 8.3.1.2.4. By Treatment
      • 8.3.1.2.5. By End User
  • 8.3.2. Germany Acute Cholecystitis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Cause
      • 8.3.2.2.3. By Diagnostic Procedure
      • 8.3.2.2.4. By Treatment
      • 8.3.2.2.5. By End User
  • 8.3.3. United Kingdom Acute Cholecystitis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Cause
      • 8.3.3.2.3. By Diagnostic Procedure
      • 8.3.3.2.4. By Treatment
      • 8.3.3.2.5. By End User
  • 8.3.4. Italy Acute Cholecystitis Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Cause
      • 8.3.4.2.3. By Diagnostic Procedure
      • 8.3.4.2.4. By Treatment
      • 8.3.4.2.5. By End User
  • 8.3.5. Spain Acute Cholecystitis Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Cause
      • 8.3.5.2.3. By Diagnostic Procedure
      • 8.3.5.2.4. By Treatment
      • 8.3.5.2.5. By End User
  • 8.3.6. Sweden Acute Cholecystitis Treatment Market Outlook
    • 8.3.6.1. Market Size & Forecast
      • 8.3.6.1.1. By Value
    • 8.3.6.2. Market Share & Forecast
      • 8.3.6.2.1. By Type
      • 8.3.6.2.2. By Cause
      • 8.3.6.2.3. By Diagnostic Procedure
      • 8.3.6.2.4. By Treatment
      • 8.3.6.2.5. By End User

9. Asia-Pacific Acute Cholecystitis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Cause
  • 9.2.3. By Diagnostic Procedure
  • 9.2.4. By Treatment
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Acute Cholecystitis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Cause
      • 9.3.1.2.3. By Diagnostic Procedure
      • 9.3.1.2.4. By Treatment
      • 9.3.1.2.5. By End User
  • 9.3.2. India Acute Cholecystitis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Cause
      • 9.3.2.2.3. By Diagnostic Procedure
      • 9.3.2.2.4. By Treatment
      • 9.3.2.2.5. By End User
  • 9.3.3. South Korea Acute Cholecystitis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Cause
      • 9.3.3.2.3. By Diagnostic Procedure
      • 9.3.3.2.4. By Treatment
      • 9.3.3.2.5. By End User
  • 9.3.4. Japan Acute Cholecystitis Treatment Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Type
      • 9.3.4.2.2. By Cause
      • 9.3.4.2.3. By Diagnostic Procedure
      • 9.3.4.2.4. By Treatment
      • 9.3.4.2.5. By End User
  • 9.3.5. Australia Acute Cholecystitis Treatment Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Type
      • 9.3.5.2.2. By Cause
      • 9.3.5.2.3. By Diagnostic Procedure
      • 9.3.5.2.4. By Treatment
      • 9.3.5.2.5. By End User
  • 9.3.6. Thailand Acute Cholecystitis Treatment Market Outlook
    • 9.3.6.1. Market Size & Forecast
      • 9.3.6.1.1. By Value
    • 9.3.6.2. Market Share & Forecast
      • 9.3.6.2.1. By Type
      • 9.3.6.2.2. By Cause
      • 9.3.6.2.3. By Diagnostic Procedure
      • 9.3.6.2.4. By Treatment
      • 9.3.6.2.5. By End User
  • 9.3.7. Bangladesh Cholecystitis Treatment Market Outlook
    • 9.3.7.1. Market Size & Forecast
      • 9.3.7.1.1. By Value
    • 9.3.7.2. Market Share & Forecast
      • 9.3.7.2.1. By Type
      • 9.3.7.2.2. By Cause
      • 9.3.7.2.3. By Diagnostic Procedure
      • 9.3.7.2.4. By Treatment
      • 9.3.7.2.5. By End User

10. South America Acute Cholecystitis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Cause
  • 10.2.3. By Diagnostic Procedure
  • 10.2.4. By Treatment
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Acute Cholecystitis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Cause
      • 10.3.1.2.3. By Diagnostic Procedure
      • 10.3.1.2.4. By Treatment
      • 10.3.1.2.5. By End User
  • 10.3.2. Argentina Acute Cholecystitis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Cause
      • 10.3.2.2.3. By Diagnostic Procedure
      • 10.3.2.2.4. By Treatment
      • 10.3.2.2.5. By End User
  • 10.3.3. Colombia Acute Cholecystitis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Cause
      • 10.3.3.2.3. By Diagnostic Procedure
      • 10.3.3.2.4. By Treatment
      • 10.3.3.2.5. By End User
  • 10.3.4. Chile Acute Cholecystitis Treatment Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Type
      • 10.3.4.2.2. By Cause
      • 10.3.4.2.3. By Diagnostic Procedure
      • 10.3.4.2.4. By Treatment
      • 10.3.4.2.5. By End User

11. Middle East and Africa Acute Cholecystitis Treatment Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Type
  • 11.2.2. By Cause
  • 11.2.3. By Diagnostic Procedure
  • 11.2.4. By Treatment
  • 11.2.5. By End User
  • 11.2.6. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Acute Cholecystitis Treatment Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Type
      • 11.3.1.2.2. By Cause
      • 11.3.1.2.3. By Diagnostic Procedure
      • 11.3.1.2.4. By Treatment
      • 11.3.1.2.5. By End User
  • 11.3.2. Saudi Arabia Acute Cholecystitis Treatment Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Type
      • 11.3.2.2.2. By Cause
      • 11.3.2.2.3. By Diagnostic Procedure
      • 11.3.2.2.4. By Treatment
      • 11.3.2.2.5. By End User
  • 11.3.3. UAE Acute Cholecystitis Treatment Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Type
      • 11.3.3.2.2. By Cause
      • 11.3.3.2.3. By Diagnostic Procedure
      • 11.3.3.2.4. By Treatment
      • 11.3.3.2.5. By End User
  • 11.3.4. Turkey Acute Cholecystitis Treatment Market Outlook
    • 11.3.4.1. Market Size & Forecast
      • 11.3.4.1.1. By Value
    • 11.3.4.2. Market Share & Forecast
      • 11.3.4.2.1. By Type
      • 11.3.4.2.2. By Cause
      • 11.3.4.2.3. By Diagnostic Procedure
      • 11.3.4.2.4. By Treatment
      • 11.3.4.2.5. By End User

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

• 14.1. Competition Outlook
• 14.2. Company Profiles (SWOT Analysis of Top 5 Players Profiled)
  • 14.2.1. Boston Scientific Corporation
  • 14.2.2. Fresenius Kabi AG
  • 14.2.3. Pfizer Inc
  • 14.2.4. Teva Pharmaceutical Industries Ltd.
  • 14.2.5. Glenmark Pharmaceuticals Limited
  • 14.2.6. Merck & Co., Inc.
  • 14.2.7. Becton, Dickinson and Company
  • 14.2.8. Simulab Corporation
  • 14.2.9. AbbVie, Inc.
  • 14.2.10. Fortimedix Surgical BV

15. Strategic Recommendations